GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • New heart drugs come in more expensive than expected Monday, 27 Jul 2015 | 6:02 AM ET

    *Sanofi, Novartis set high prices for Praluent, Entresto. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. Sanofi and Regeneron, which won U.S. approval on Friday for Praluent to treat stubbornly high...

  • EAST RUTHERFORD, N.J.— A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. The drug, known chemically as sonidegib, is a daily pill developed by Swiss drugmaker Novartis AG, which has U.S. pharmaceuticals headquarters in East Hanover, New Jersey. Novartis hasn't...

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • FDA approves Novartis's advanced skin cancer drug Friday, 24 Jul 2015 | 12:19 PM ET

    July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer.

  • July 23- Eli Lilly and Co's quarterly sales rose for the first time in seven quarters, helped by demand for its new diabetes and cancer drugs as well as the acquisition of Novartis AG's animal health business. Lilly's net profit fell to $600.8 million, or 56 cents per share, from $733.5 million, or 68 cents per share, a year earlier. It also bumped up the lower end of its...

  • July 23- Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business. The Indianapolis- based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a...

  • Eli Lilly tops Street 2Q forecasts, raises outlook Thursday, 23 Jul 2015 | 6:36 AM ET

    NEW YORK— Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 74 cents per share. Six analysts surveyed by Zacks expected $4.84 billion in revenue.

  • *Wall Street slides with earnings in focus. Stocks on Wall Street fell, with results from bellwethers IBM and United Technologies weighing the most on the S&P 500, while Apple slumped 7 percent late after posting earnings. "For the first time in a while fundamentals seem to be driving the action today in an otherwise very quiet macro backdrop and probably will...

  • WASHINGTON— A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication. Novartis received federal approval in March to sell its cheaper copy of Amgen's Neupogen, which is used to boost blood cells in cancer patients.

  • NEW YORK, July 21- Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio, the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion- a-year anti-infection drug Neupogen, a U.S. appeals court said on Tuesday. The ruling stemmed from a lawsuit that Amgen filed last October in federal court in San Francisco in...

  • Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more Tuesday, 21 Jul 2015 | 8:04 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • European shares fall, pulled down by drugmakers Tuesday, 21 Jul 2015 | 7:51 AM ET

    *Pharmaceuticals drop after Novartis results. LONDON, July 21- European shares retreated on Tuesday from their six-week high in the previous session, with the healthcare leading the market lower after Novartis reported quarterly incomes below analysts' expectations. Novartis dropped 2.1 percent after the Swiss drugmaker reported a weak performance by its...

  • Novartis' now offers generic MS drug: CEO Tuesday, 21 Jul 2015 | 6:13 AM ET
    Novartis' now offers generic MS drug: CEO

    Joe Jimenez, Novartis CEO, discusses the generic availability of its multiple-sclerosis drug Copaxone.

  • Novartis' new heart drug potential game changer: CEO Tuesday, 21 Jul 2015 | 6:09 AM ET
    Novartis' new heart drug potential game changer: CEO

    Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.

  • *Gold gains after plunging over 4 pct to 5- yr lows. LONDON, July 21- Gold prices steadied on Tuesday after plunging more than 4 percent in recent sessions, but remained under pressure as the dollar touched a three-month high on firming expectations of an interest rate hike. "Greece may be easing us into the quieter summer months, however there is still plenty to focus...

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.

  • *Novartis leads market lower after results. LONDON, July 21- European shares edged lower on Tuesday after hitting a six-week high in the previous session, with the healthcare sector leading the market lower after Novartis reported quarterly incomes below analysts' expectations. The STOXX Europe 600 Healthcare Index fell 1.0 percent, the top sectoral decliner...

  • BERLIN— Swiss-based pharmaceutical giant Novartis' second-quarter net income dropped 32 percent over the same quarter last year, brought down primarily by poor performance from associated companies and negative effects of a strong U.S. dollar, the company said Tuesday. Group sales are expected to grow by mid-single digits and operating income is expected...

  • Strong dollar hits Novartis; reports profit miss Tuesday, 21 Jul 2015 | 3:06 AM ET

    Swiss drugmaker Novartis reported second-quarter core net income that fell short of expectations on Tuesday, on the back of a stronger dollar.

  • Looking at bolt-on acquisitions: Novartis CEO Tuesday, 21 Jul 2015 | 1:45 AM ET
    Looking at bolt-on acquisitions: Novartis CEO

    Joe Jimenez, CEO of Novartis, says the company is looking for bolt-on acquisitions worth between $1 bilion to $3 billion, rather than mega-mergers.